The opioid abuse epidemic is expanding in the United States (US), and increasingly affects other nations, spurring the search for therapeutic agents that are not themselves μ-opioid agonists. The authors found that cannabidiol (CBD; from cannabis [Cannabis sativa, Cannabaceae]) reduced craving and anxiety associated with heroin-seeking behavior triggered by drug cues in vivo. Drug cues contribute to relapse in drug-abstinent individuals and are strong triggers for craving, a core component of opioid use disorder (OUD). Preclinical findings show that CBD’s reduction of heroin-seeking behavior lasts for “weeks.” Other in vivo studies report similar results for CBD in reducing contextual memories associated with drug-seeking behavior for other agents. A clinical trial found CBD to be associated with a less attentional bias to cigarette cues in tobacco (Nicotiana tabacum, Solanaceae) users. Clinical trials found high-dose CBD to be safe and without adverse effects (AEs), even when co-exposed with…